OBJECTIVES: Endoscopic eradication therapy is used to treat mucosal neoplasms in
Barrett's esophagus, but cannot cure cancers that have metastasized to lymph nodes. The …

Background & Aims: Recent studies have claimed long neoplasia-free survival rates with
endoscopic mucosal resection of high-grade dysplasia (HGD) in Barrett's esophagus (BE) …

BACKGROUND: The rate of occult adenocarcinoma at esophagectomy in patients with
Barrett's esophagus (BE) and high-grade dysplasia (HGD) has been reported to be …

Importance Barrett esophagus, a complication of gastroesophageal reflux disease (GERD),
predisposes patients to esophageal adenocarcinoma, a tumor that has increased in …

OBJECTIVES: Patients with Barrett's esophagus (BE) have an increased risk of developing
esophageal adenocarcinoma (EAC). As the absolute risk remains low, there is a need for …

Dysplasia is a very imperfect biomarker for malignancy in Barrett's esophagus. Invasive
cancer has been found in 30–40% of esophagi resected because preoperative endoscopic …

BACKGROUND: Esophagectomy for early esophageal adenocarcinoma is associated with
increased operative mortality and morbidity, but possibly a decreased recurrence rate …

OBJECTIVES Although EMR has been used for elimination of neoplasia in BE, the
significance of positive carcinoma margins and depth of invasion on endoscopic resection …

Background Intestinal metaplasia of the distal esophagus frequently cannot be detected in
patients with esophageal adenocarcinoma. It has therefore been questioned whether …

BACKGROUND: Endoscopic therapies for early neoplasia in Barrett's esophagus may be a
viable alternative to esophagectomy. OBJECTIVE: Our purpose was to compare endoscopic …